ADULT: VFib or Pulseless VTach: 300 mg IV or IO. May repeat ½ initial dose (150 mg) no faster than 10 min. Or under
May repeat ½ initial dose (150 mg) no faster than 10 min. Or under VFib or Pulseless VTach, if patient converts with ROSC from a ventricular arrhythmia and
Drug of 2nd choice (vs amiodarone) to terminate VTach and prevent VFib after DC cardioversion Adenosine binds to adenosine receptors in heart tissue
VFib - Ventricular Fibrillation. VTach or VT - Ventricular Drug of 2nd choice (vs amiodarone) to terminate VTach and prevent VFib after DC cardioversion.
Side Effects: Bradycardia; Hypotension. Adult Dose: Standing order: Ventricular fibrillation (VF); Pulseless ventricular tachycardia (pulseless VTach);. First
Lidocaine: Drug of 2nd choice (vs amiodarone) to terminate VTach and prevent VFib after DC cardioversion. Used only in a
Identify major drug-specific side effects of commonly used antiarrhythmics (e.g. beta blockers, amiodarone, lidocaine). VTach or VT - Ventricular Tachycardia.
Describe the ACLS algorithm for cardiac arrest due to Vfib or pulseless Vtach - amiodarone IV/IO first dose 300 mg - second dose 150 mg.
ADULT: VFib or Pulseless VTach: 300 mg IV or IO. May repeat ½ initial dose (150 mg) no faster than 10 min. Or under
Comments